nach oben

Erschienen in:

01.03.2014 | Clinical Study

CSF CA 15-3 in breast cancer-related leptomeningeal metastases

verfasst von: Emilie Le Rhun, Andrew Kramar, Sophie Salingue, Marie Girot, Isabelle Rodrigues, Audrey Mailliez, Fahed Zairi, Edgar Bakhache, Yves Marie Robin, Sophie Taillibert, François Dubois, Jacques Bonneterre, Marc C. Chamberlain

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The sensitivity of CSF cytology, the standard method for diagnosis of leptomeningeal metastases (LM), is low. Serum cancer antigen 15-3 (CA 15-3) is frequently used for the monitoring of patients with breast cancer (BC) and is a laboratory test available in most centers. The aim of the current study was to determine the feasibility of measuring CSF CA 15-3 and CA 15-3 CSF/serum ratio in patients with BC-related LM. Serum and CSF CA 15-3 values were evaluated in 20 BC patients with LM (Group 1), 20 patients with LM from other primary cancers (Group 2), 20 BC patients with parenchymal brain metastases only (Group 3) and 20 controls (Group 4). CSF and serum were collected on the same day. Serum and CSF CA 15-3 were assessed by an automatized immuno-enzymatic technology (TRACE^® technology, KRYPTOR Automate, Brahms Society, France). In univariate analysis, BC patients with LM (Group 1) compared to other groups, a significantly elevated serum CA 15-3 (median 51 U/ml, range 12–2819) and CSF CA 15-3 (median 8.7 U/ml, range 0.1–251) was observed. Additionally, the CSF/serum ratio of CA 15-3 was significantly higher in this group of patients (median 0.18, range 0.002–4.40). Multivariate analysis identified a cut-off for CSF CA15-3 with 80 % sensitivity and 70 % specificity. Conclusions: The current study confirms the feasibility of determining CSF CA 15-3 using a widely available technology. Evaluation of the CSF CA 15-3 may be useful in the diagnosis and management of BC-related LM but further studies are needed.

de Azevedo CR, Cruz MR, Chinen LT, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, Fanelli MF, Gimenes DL (2011) Meningeal carcinomatosis in breast cancer: prognostic factors and outcomes. J Neurooncol 104(2):565–572PubMedCrossRef

Rudnika H, Niwinska A, Murawska M (2007) Breast cancer leptomeningeal metastasis - the role of a multimodality treatment. J Neurooncol 84:57–62CrossRef

Clatot F, Philippin-Lauridant G, Ouvrier O, Nakry T, laberge-Le-Couteulx S, Guillemet C, Veyret C, Blot E (2009) Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neurooncol 95:421–426

Gauthier H, Guilhaume MN, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Diéras V (2010) Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21:2183–2187PubMedCrossRef

Lee S, Ahn HK, Nam do H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH (2011) Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 129(3):809–817

Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, André C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 113(1):83–92PubMedCrossRef

Lara-Medina F, Crismatt A, Villarreal-Garza C, Alvarado-Miranda A, Flores-Hernández L, González-Pinedo M, Gamboa-Vignolle C, Ruiz-González JD, Arrieta O (2012) Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J 18(3):233–241PubMedCrossRef

Meattini I, Livi L, Saieva C, Franceschini D, Marrazzo L, Greto D, Scotti V, Scoccianti S, Paiar F, Bordi L, Nori J, Sanchez L, Orzalesi L, Bianchi S, Biti G (2012) Prognostic factors and clinical features in patients with leptomeningeal metastases from breast cancer: a single center experience. J Chemother 24(5):279–284PubMedCrossRef

Regierer AC, Stroux A, Kühnardt D, Dieing A, Lehenbauer-Dehm S, Flath B, Possinger K, Eucker J (2008) Contrast-enhancing meningeal lesions are associated with longer survival in breast cancer related leptomeningeal metastasis. Breast Care 3(2):118–123PubMedCentralPubMedCrossRef

10.

Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O’Day SJ, Akerley W, Allen J, Baidas S, Gerlier SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cphn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russel C, Shapiro W, Swinnen L, Howell SB (2001) Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabrine. Br J Cancer 84:157–163PubMedCentralPubMedCrossRef

11.

National Comprehensive Cancer Network Guidelines® (NCCN Guidelines®) (2013) Clinical practice guidelines in oncology central nervous system cancers. Version 2.2012. NCCN.org. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 13 July 2013

12.

Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Fine HA, Friedman A, Glass J, Grossman SA, Heimberger AB, Junck L, Levin V, Loeffler JJ, Maor MH, Narayana A, Newton HB, olivi A, Portnow J, Prados M, Raizer JJ, Rosenfeld SS, Shrieve DC, Stills AK Jr, Spence AM, Vrionis FD, National Comprehensive Cancer Network (2005) Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw 3:644–690

13.

Glass JP, Melamed M, Chernik NL, Posner JB (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369–1375PubMedCrossRef

14.

Chamberlain MC, Glantz M, Groves MD, Wilson WH (2009) Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk and determining benefit of treatment. Semin Oncol 36:S35–S45PubMedCrossRef

15.

Glantz MJ, Cole BF, Cobb J, Mills P, Lekos A, Walters BC, Recht LD (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82:733–739PubMedCrossRef

16.

Weston CL, Glantz MJ, Connor JR (2011) Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. Fluids Barriers CNS 8:14PubMedCentralPubMedCrossRef

17.

Walbert T, Groves MD (2010) Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Future Oncol 6:287–297PubMedCrossRef

18.

Corsini E, Bernardi G, Gaviani P, Silvani A, de Grazia U, Ciusani E, Croci D, Salmaggi A (2009) Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med 47:874–879

19.

Herrlinger U, Fösrschier H, Küker W, Meyermann R, Bamberg M, Dichgns J and Weller: M (2004) Leptomeningeal metastasis: survival and prognosis in 155 patients. J Neurol Sci 223(2):167–178

20.

Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, Geurts-Moespot A, Visser MC, Taphoorn MJ (2005) CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 65(7):1120–1122PubMedCrossRef

21.

van de Langerijt B, Gijtenbeek JM, de Reus HP, Sweep FC, Geurts-Moespot A, Hendriks JC, Kappelle AC, Verbeek MM (2006) CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 67(1):114–119PubMedCrossRef

22.

Groves M, Hess PVK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli Yung WK, Liu TJ (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94:229–234PubMedCrossRef

23.

Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, El-Deiry WS (2011) Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2:752–760PubMed

24.

Le Rhun E, Tu Q, De Carvalho Bittencourt M, Farre I, Mortier L, Cai H, Kohler C, Faure GC (2013) Detection and quantification of CSF malignant cells by the cell search technology in patients with melanoma leptomeningeal metastasis. Med Oncol 30(2):538

25.

Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, Deangelis LM, Omuro A (2013) Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 80(17):1598–1605PubMedCrossRef

26.

Römpp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, Spengler B, Heeren R, Smitt PS, Luider TM (2007) Identification of leptomeningeal metastasis-related proteins in cerebro-spinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nano LC-FTICR MS. Proteomics 7:474–481PubMedCrossRef

27.

Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Smitt PA (2005) MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 4(9):1341–1349PubMedCrossRef

28.

Brandsma D, Voest EE, de Jager W, Bonfrer H, Algra A, Boogerd W, Korse T, Reijneveld JC, Verbeek MM, Rijkers G, Taphoorn MJ (2006) CSF protein profiling using multiplex immuno-assay: a potential new diagnostic tool for leptomeningeal metastases. J Neurol 253(9):1177–1784PubMedCrossRef

29.

Boogerd W, Vroom TM, van Heerde P, Brutel de la Rivière G, Peterse JL, van der Sande JJ (1988) CSF cytology versus immunocytochemistry in meningeal carcinomatosis. J Neurol Neurosurg Psychiatry. 51(1):142–145

30.

Bougel S, Lhermitte B, Gallagher G, de Flaugergues JC, Janzer RC, Benhattar J (2013) Methylation of the hTERT promoter: a novel cancer biomarker for leptomeningeal metastasis detection in cerebrospinal fluids. Clin Cancer Res 19(8):2216–2223PubMedCrossRef

31.

Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, babain R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Hotlen-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih leM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry (2008) National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:11–79

32.

Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voltot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45:1695–1707PubMed

33.

Martin PM (2007) Bilan et recommandations pour l’utilisation des marqueurs tumoraux sériques dans le cadre des cancers du sein en 2007 (French). In: Cancer du sein: Compte-rendu du cours supérieur francophone de cancérologie de Saint-Paul-de Vence, 18–20 janvier 2007. Springe, New York, pp 197–202

34.

Vassault A, Grafmeyer D, Naudin C, Dumont G, Bailly M, Henry J, Gerhardt MF (1986) Protocole de validation des techniques (document B) (French). Ann Biol Clin (Paris) 44:686–745

35.

Gauchez AS, Pez E, Boutonnat J, Bourre JC, Pelletier L, Payan R, Mousseau M (2007) Early detection of leptomeningeal metastasis in patients with metastatic breast carcinoma: validation of CA 15-3 measurement in cerebrospinal fluid (French). Ann Biol Clin (Paris) 65(6):653–658

36.

Bidard FC, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Cottu P, Beuzeboc P, Rolland E, Mathiot C, Pierga JY (2012) Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res 14(1):R29PubMedCentralPubMed

37.

Guepratte S, Pallud C, Pichon MF (2002) Dosage des marqueurs tumoraux ACE, CA 15.3, CA 125, CA 19.9 dans les liquides d’épanchement et le LCR par immunoanalyse en phase homogène. Corrélation avec les résultats cytologiques et les concentrations sériques. Immuno-analyse et Biologie spécialisée, pp 18–25. http://www.em-consulte.com/article/12339/dosage-des-marqueurs-tumoraux-ace-ca-15-3-ca-125-e. Accessed 7 July 2013

38.

Kang SJ, Kim KS, Ha YS, Huh SY, Lee JH, Kim JK, Kim MJ (2010) Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis. J Clin Neurol 6(1):33–37PubMedCentralPubMedCrossRef

39.

Demopoulos A (2004) Leptomeningeal metastases. Curr Neurol Neurosci Rep 4:196–204PubMedCrossRef

40.

DeAngelis LM (1988) Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38(2–3):245–252

Titel: CSF CA 15-3 in breast cancer-related leptomeningeal metastases
verfasst von: Emilie Le Rhun
Andrew Kramar
Sophie Salingue
Marie Girot
Isabelle Rodrigues
Audrey Mailliez
Fahed Zairi
Edgar Bakhache
Yves Marie Robin
Sophie Taillibert
François Dubois
Jacques Bonneterre
Marc C. Chamberlain
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1361-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Detection of primary cilia in human glioblastoma

Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation

Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme

Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas